Truist cuts target for Integra LifeSciences stock to USD 15.00
Published on 10/15/2026 at 22:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSResearch and reporting dates
- Truist lowered its target from USD 19.00 to USD 15.00 on October 14, 2026.
- Second-quarter revenue reached USD 418.76 million versus USD 417.54 million consensus.
- Integra LifeSciences stock costs EUR 12.15 at 10:01 p.m. CEST at Lang & Schwarz on October 15, 2026, up 2.66 percent on Nasdaq.
- Integra LifeSciences is scheduled to report third-quarter results on October 21, 2026.
Truist lowered its price target for Integra LifeSciences from USD 19.00 to USD 15.00 on October 14, 2026, according to Markets Insider. The new target stood 10.86 percent above the USD 13.53 Nasdaq price at the October 15, 2026 close. At Lang & Schwarz, the stock was trading at EUR 12.15 on October 15, 2026 at 10:01 p.m. CEST, while the Nasdaq price was up 2.66 percent on the day.
Revenue beats the quarterly estimate
Integra reported second-quarter 2026 revenue of USD 418.76 million, compared with USD 417.54 million consensus, according to MarketBeat. The figure was reported for the quarter ended June 30, 2026, after the company published its results on July 29, 2026. That comparison gives the latest reported operating figure a clearer market context than the target revision alone.
Price remains below the yearly high
The Nasdaq price was USD 13.53 at 4:00 p.m. ET on October 15, 2026. It stood 33.97 percent below the 52-week high of USD 20.49 and 55.52 percent above the 52-week low of USD 8.70. Trading volume reached 1,171,800 shares, 26.89 percent above the average volume of 923,562 shares.
The October 14 target reduction followed a series of lower analyst targets after Integra updated its 2026 outlook earlier in October. That earlier company update is treated here only as dated background, while the latest market focus is the Truist target and the next reporting date.
Valuation and the next report
Integra had a market capitalization of USD 1.1 billion and a price-to-earnings ratio of minus 146.11 as of October 15, 2026. The company is scheduled to release third-quarter 2026 results on October 21, 2026, a date listed by Markets Insider.
Comparison with peers
Integra LifeSciences (Nasdaq, USD): plus 2.66 percent, P/E minus 146.11, market capitalization USD 1.1 billion
Medtronic (NYSE, USD): plus 1.32 percent, P/E 23.51, market capitalization USD 122.1 billion
Boston Scientific (NYSE, USD): plus 2.69 percent, P/E 17.95, market capitalization USD 64.0 billion
Market position in euros
The euro quotation puts Integra at EUR 12.15 in late trading at Lang & Schwarz on October 15, 2026 at 10:01 p.m. CEST. The Nasdaq move and the 52-week placement provide the key cross-checks for investors comparing the German quotation with the US listing.
The further course of trading is shown by the continuously updated real-time quote of Integra LifeSciences stock.
Integra LifeSciences Holdings Corporation market data
- Company: Integra LifeSciences Holdings Corporation
- ISIN: US4579852082
- Ticker: IART
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 15, 2026, 10:01 p.m. CEST): EUR 12.15
- Change on Nasdaq versus the prior close: plus 2.66 percent
- Market capitalization: USD 1.1 billion (as of October 15, 2026)
- 52-week range: USD 8.70-20.49 (as of October 15, 2026)
- Sector / Industry: Healthcare / Medical Devices
Market context: Market report Nasdaq Composite.
